Antibiotic Eye Drops: Indications, Rational Use and Antimicrobial Stewardship in Indian Practice

Topical antibiotics are among the most frequently prescribed ophthalmic preparations in India — and among the most frequently misused. A bottle of antibiotic eye drops is dispensed for red eyes that are viral, allergic or simply dry; courses are truncated at three days or stretched for months; prophylaxis becomes habit rather than decision. Against a backdrop of rising antimicrobial resistance (AMR) — a crisis India knows well from systemic medicine — ophthalmology cannot afford to treat topical antibiotics as benign. This article sets out the legitimate indications for antibiotic eye drops, how to select an agent, and what stewardship looks like in an eye clinic.

Legitimate Indications

Antibiotic eye drops have a defensible role in a defined, relatively short list of situations:

• Acute bacterial conjunctivitis — where treatment shortens disease duration and reduces transmission, particularly in contact lens wearers, school-age children and institutional settings.
• Bacterial keratitis — sight-threatening; requires aggressive, often fortified therapy guided by scraping and culture.
• Perioperative prophylaxis — cataract, refractive, glaucoma and vitreoretinal surgery; intravitreal injection prophylaxis (itself increasingly questioned).
• Blepharitis with staphylococcal lid disease — short courses of antibiotic or antibiotic-steroid combinations to the lid margin.
• Prophylaxis after corneal trauma, foreign body removal or chemical injury with epithelial breach.
• Chlamydial and gonococcal conjunctivitis — topical therapy as an adjunct to mandatory systemic treatment.

What is conspicuously absent from this list: viral conjunctivitis, allergic conjunctivitis, dry eye, episcleritis, and "red eye, cause unclear". The majority of acute conjunctivitis presentations in adult outpatients are viral; antibiotics neither shorten the illness nor prevent the (rare) secondary bacterial infection.

Choosing an Agent: Spectrum, Penetration, Toxicity

The guiding principle: use the narrowest agent that reliably covers the likely pathogen, at a dose and duration that eradicate rather than inconvenience the organism.

The Resistance Picture: What Surveillance Tells Us

The ARMOR study (Antibiotic Resistance Monitoring in Ocular micRoorganisms), the only longitudinal ocular-specific surveillance programme of its kind, reported its 10-year analysis in JAMA Ophthalmology (Asbell et al., 2020): roughly a third of Staphylococcus aureus and half of coagulase-negative staphylococcal ocular isolates were methicillin-resistant, and methicillin-resistant isolates showed 70–85% multidrug resistance, including to fluoroquinolones. Streptococcal resistance to macrolides approached 40%. Indian microbiology literature mirrors this: fluoroquinolone susceptibility among ocular staphylococci has eroded steadily over two decades.

Two further findings should shape prescribing:

• Kim and Toma (Ophthalmology, 2010–2011) showed that repeated topical fluoroquinolone exposure around intravitreal injections selects resistant conjunctival and nasopharyngeal flora — a direct demonstration that our prophylaxis habits alter the patient's ocular microbiome.
• Periodic exposure, not just chronic use, selects resistance. Even a 5–7 day conjunctivitis course changes flora transiently; cumulative courses across a surgical career's worth of patients shift population-level susceptibility.

Stewardship in the Eye Clinic: Eight Practical Rules

1. Diagnose before you prescribe. Purulent discharge, matting and papillary reaction suggest bacterial conjunctivitis; watery discharge with preauricular nodes suggests viral. When in doubt, treat the likely diagnosis — not the prescription pad.
2. Culture sight-threatening infection. Every corneal ulcer gets scraped before the first drop where facilities permit.
3. Treat to eradicate, then stop. Defined courses (5–7 days for conjunctivitis; 1–2 weeks postoperatively). Never taper antibiotics.
4. Reserve fourth-generation fluoroquinolones for keratitis, surgical prophylaxis and culture-directed use — not routine conjunctivitis where narrower agents suffice.
5. Reconsider prophylaxis around intravitreal injections — growing evidence suggests it adds little beyond povidone-iodine and may breed resistance.
6. Do not continue antibiotic drops for non-healing epithelial defects — the preservative and the drug itself may be the problem.
7. Use antibiotic-steroid combinations only when both components are genuinely indicated, such as Tobalux-F for staphylococcal blepharokeratoconjunctivitis — never as a default red-eye remedy.
8. Audit your own prescribing. A quarterly review of indication, agent and duration is the simplest stewardship intervention available to a solo practitioner.

A Quick Reference: Matching the Red Eye to the Right Response

Most stewardship failures are visible in this table: the antibiotic prescribed for rows two, three, four and six does no good and measurable collective harm. Printing it for the consulting room is not beneath a senior clinician — it is how habits actually change.

What About Combination Antibiotic Drops?

Multi-antibiotic preparations (polymyxin B-neomycin-gramicidin and similar) persist in the Indian market. Their logic is broad spectrum without fluoroquinolone exposure; their liabilities are neomycin contact dermatitis (surprisingly common), poor intraocular penetration, and coverage gaps against the organisms that matter most in keratitis. They retain a narrow role in superficial conjunctival and lid-margin infection where cost dominates, but they are not prophylaxis agents and not keratitis agents. Similarly, antibiotic-steroid combinations have a defined but narrow indication list covered elsewhere in this series — they are emphatically not a compromise for the prescriber uncertain whether a red eye is infective or inflammatory; that uncertainty is resolved at the slit lamp, not at the pharmacy.

Bacterial Keratitis: Stewardship Under Pressure

Keratitis is where rational prescribing matters most and where it most often breaks down. The reflex "moxifloxacin hourly" for every ulcer ignores two realities: central, deep or large ulcers (>2 mm, or with hypopyon) demand scraping, culture and fortified therapy; and fungal keratitis — disproportionately common in India, particularly after vegetative trauma — is worsened by antibiotic-only empiricism that delays natamycin. A disciplined keratitis pathway:

1. Scrape for Gram/KOH stain and culture before the first drop whenever the ulcer is sight-threatening, atypical, or unresponsive after 48 hours.
2. Start broad but reasoned: fortified cefazolin plus tobramycin, or fourth-generation fluoroquinolone monotherapy for small peripheral ulcers.
3. Review at 24–48 hours against clinical response and microbiology; narrow or switch deliberately, not impulsively.
4. Document stop dates. Keratitis therapy has an end-point — re-epithelialisation with sterilisation — not an open bottle.

Working With the System You Actually Practice In

Stewardship fails when it ignores real behaviour. Three levers work in Indian outpatient settings:

• Write stop dates on prescriptions. "Moxifloxacin QID × 7 days, then stop" prevents the month-long leftover-bottle habit better than any lecture.
• Brief your local chemists. A two-minute conversation with the pharmacies your patients actually use — explaining that repeated dispensing of antibiotic drops without review delays keratitis diagnoses — changes more behaviour than guideline documents.
• Use follow-up as the safety net. If you choose not to prescribe an antibiotic for a viral-looking conjunctivitis, schedule (or offer) review within a week and tell the patient explicitly what should trigger earlier return. Confidence in the diagnosis, communicated clearly, is what patients mistake for a prescription.

The Policy Backdrop

India's regulatory environment is slowly tightening: the Red Line campaign marked prescription-only antibiotics, Schedule H1 brought compulsory record-keeping for key systemic agents, and CDSCO oversight of fixed-dose combinations has culled irrational products. Topical ophthalmics sit at the edge of these mechanisms — enforcement remains weak at retail level — but institutional protocols, hospital antibiotic policies and AIOS-endorsed prophylaxis guidance give ophthalmologists a framework to practise rationally regardless of retail chaos. Quality assurance matters here too: a correctly concentrated, sterile, preservative-appropriate formulation from a WHO-GMP facility is itself a stewardship measure, because under-potent or contaminated drops breed both treatment failure and resistance.

Finally, stewardship is also a documentation habit. Record the indication, agent, concentration and planned stop date in the case notes for every antibiotic prescribed. When that patient returns in six months with a corneal ulcer, the prior exposure history may determine whether your first-line fluoroquinolone is still a rational choice.

The Indian Context

Several features of Indian practice amplify the stewardship problem: over-the-counter availability of antibiotic drops despite Schedule H status, patient expectation of a prescription at every visit, chemist-driven self-medication between consultations, and enormous surgical volumes generating correspondingly large prophylaxis volumes. Counterbalancing this is an opportunity: ophthalmologists are among the highest-volume antibiotic prescribers by encounter, and disciplined prescribing in eye care is a meaningful contribution to national AMR containment. CDSCO-regulated fixed-dose combinations, quality-assured manufacturing and rational brand selection are part of the same equation — a reliable, correctly concentrated generic such as Moxilux prescribed for the right indication beats a dubious brand prescribed reflexively.

Frequently Asked Questions

Do all cases of conjunctivitis need antibiotic eye drops?

No. Most adult conjunctivitis is viral and self-limiting. Antibiotics are indicated for purulent bacterial conjunctivitis, in contact lens wearers, and where chlamydial or gonococcal disease is suspected — alongside systemic therapy for the latter two.

Which antibiotic eye drop is best for bacterial conjunctivitis?

For routine community-acquired disease, a narrow agent (e.g., tobramycin or chloramphenicol) is adequate. Reserve moxifloxacin for contact lens-related disease, surgical patients and recurrent infection, to protect its utility for keratitis and prophylaxis.

How long should a course of antibiotic eye drops last?

Bacterial conjunctivitis: 5–7 days. Postoperative prophylaxis: 7–14 days. Keratitis: until re-epithelialisation with clinical resolution, guided by culture. Extend only with a documented reason.

Are antibiotic eye drops needed after intravitreal injections?

Evidence increasingly suggests povidone-iodine antisepsis alone is sufficient, and repeated fluoroquinolone exposure selects resistant flora. Many retina specialists have abandoned routine post-injection antibiotics; follow your institutional protocol.

Can patients buy antibiotic eye drops over the counter in India?

They are Schedule H prescription drugs, but OTC dispensing is common. Counsel patients against self-medication and leftover-bottle reuse — both drive resistance and mask serious diagnoses such as keratitis or uveitis.

---

This article is for educational purposes for healthcare professionals and does not replace clinical judgement or local antimicrobial policy. Culture results and institutional antibiograms should guide therapy for serious infection.

Oculentis Medical is committed to rational antibiotic use and quality-assured ophthalmic formulations. To discuss our antibiotic portfolio or request prescribing information, request a sample or contact us.